Unity Biotechnology Inc Expected To Post A Loss Of 96 Cents A Share: Earnings Preview

Unity Biotechnology

04/11/2023 03:08

* UNITY Biotechnology Inc  UBX.OQ   UBX.O  is expected
to show no
change in quarterly revenue when it reports  results 
    * 
    * ​Refinitiv's mean analyst estimate for UNITY Biotechnology
Inc
is for a loss of 96 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for UNITY
Biotechnology Inc is $6​, above​ its last closing price
of $2.06. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.83       -0.86      -0.85     Beat    0.7
 Mar. 31 2023  -1.08       -1.08      -0.76     Beat    29.9
 Dec. 31 2022  -1.01       -1.05      -1.00     Beat    4.6​
 Sep. 30 2022  -1.62       -1.65      -1.36     Beat    17.4
 ​​Jun.        -2.70       -2.80      -1.90     Beat    32.1
 30 2022                                                
 Mar. 31 2022  -2.52       -2.57      -2.80     Missed  -8.8​
 Dec. 31 2021  -3.06       -3.85      -1.80     Beat    53.2
 Sep. 30 2021  -3.77       -3.71      -3.00     Beat    19.2
 This summary was machine generated November 4 at 03:08 GMT.  All
figures in US dollars  unless otherwise stated